Yu Gordon H, Maisel Julia, Frank Renee, Pukenas Bryan A, Sebro Ronnie, Weber Kristy
Department of Pathology & Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania.
Department of Pathology & Laboratory Medicine, Geisinger Medical Laboratories, Danville, Pennsylvania.
Diagn Cytopathol. 2017 Jul;45(7):608-613. doi: 10.1002/dc.23735. Epub 2017 May 3.
Fine-needle aspiration (FNA) is utilized in the diagnostic work-up of bone lesions in a number of institutions, either in isolation or in conjunction with core biopsy. We report our experience with FNA of bone-based lesions, including comparison of this approach with concurrent core biopsy specimens.
Retrospective review over a 5-year period (2011-2015) revealed 233 cases of bone FNAs.
The most commonly encountered diagnosis was malignant neoplasm (160 cases, 68.7%); within this group of malignancies, 103 cases (64.4%) represented metastatic carcinoma. Benign lesions were encountered infrequently (9 cases, 3.9%). While 37 cases (15.9%) revealed "no evidence of malignancy," 12 cases (5.2%) showed atypical findings, 3 cases (1.3%) demonstrated inflammatory conditions, and 12 aspiration biopsies were deemed nondiagnostic (5.2%). In 202 cases, concurrent core biopsies were performed following FNA and rapid on-site evaluation (ROSE). Comparison of the FNA and core biopsy diagnoses among malignant neoplasms revealed 19 diagnostic discrepancies, including 16 cases with a false-negative FNA (7.9% of all FNAs with concurrent core biopsy) and 3 cases with a false-negative core biopsy (1.5% of all cases with corresponding FNA).
Our findings indicate that FNA of bone lesions is a useful diagnostic technique with high sensitivity, particularly when the cytologic findings are interpreted in conjunction with the core biopsy and pertinent clinical and radiologic findings. In addition, ROSE followed by open, dynamic communication with the performing radiologist leads to an extremely low rate of inadequate core biopsy specimens, resulting in optimal patient diagnosis and management. Diagn. Cytopathol. 2017;45:608-613. © 2017 Wiley Periodicals, Inc.
在许多机构中,细针穿刺抽吸术(FNA)被用于骨病变的诊断检查,可单独使用,也可与粗针活检联合使用。我们报告了我们在基于骨的病变FNA方面的经验,包括将这种方法与同期粗针活检标本进行比较。
回顾性分析5年期间(2011 - 2015年)的233例骨FNA病例。
最常见的诊断是恶性肿瘤(160例,68.7%);在这组恶性肿瘤中,103例(64.4%)为转移性癌。良性病变很少见(9例,3.9%)。虽然37例(15.9%)显示“无恶性证据”,12例(5.2%)显示非典型发现,3例(1.3%)表现为炎症情况,12例穿刺活检被认为无法诊断(5.2%)。在202例中,FNA后进行了同期粗针活检及快速现场评估(ROSE)。恶性肿瘤中FNA和粗针活检诊断的比较显示有19例诊断差异,包括16例假阴性FNA病例(占所有同期粗针活检FNA的7.9%)和3例假阴性粗针活检病例(占所有相应FNA病例的1.5%)。
我们的研究结果表明,骨病变的FNA是一种有用的诊断技术,具有高敏感性,特别是当细胞学结果与粗针活检以及相关的临床和放射学结果相结合进行解释时。此外,ROSE后与执行放射科医生进行开放、动态的沟通,导致粗针活检标本不足的发生率极低,从而实现对患者的最佳诊断和管理。诊断细胞病理学。2017;45:608 - 613。©2017威利期刊公司。